These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27347712)

  • 21. [New antibiotics - standstill or progress].
    Rademacher J; Welte T
    Med Klin Intensivmed Notfmed; 2017 Apr; 112(3):206-213. PubMed ID: 28314920
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamics, pharmacokinetics and clinical efficacy of telavancin in the treatment of pneumonia.
    Adamantia L; Antoni T
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):803-12. PubMed ID: 27158752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems.
    Kollef MH
    Respir Care; 2004 Dec; 49(12):1530-41. PubMed ID: 15571647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bradley JS
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S136-43. PubMed ID: 20597664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High prevalence of multidrug-resistant nonfermenters in hospital-acquired pneumonia in Asia.
    Chung DR; Song JH; Kim SH; Thamlikitkul V; Huang SG; Wang H; So TM; Yasin RM; Hsueh PR; Carlos CC; Hsu LY; Buntaran L; Lalitha MK; Kim MJ; Choi JY; Kim SI; Ko KS; Kang CI; Peck KR;
    Am J Respir Crit Care Med; 2011 Dec; 184(12):1409-17. PubMed ID: 21920919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceftobiprole for the treatment of pneumonia.
    Cillóniz C; Dominedò C; Garcia-Vidal C; Torres A
    Rev Esp Quimioter; 2019 Sep; 32 Suppl 3(Suppl 3):17-23. PubMed ID: 31364337
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentially multidrug-resistant non-fermentative Gram-negative pathogens causing nosocomial pneumonia.
    Ferrara AM
    Int J Antimicrob Agents; 2006 Mar; 27(3):183-95. PubMed ID: 16472990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug-resistant pathogens and pneumonia: comparing the trauma and surgical intensive care units.
    Becher RD; Hoth JJ; Neff LP; Rebo JJ; Martin RS; Miller PR
    Surg Infect (Larchmt); 2011 Aug; 12(4):267-72. PubMed ID: 21524206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of gram-negative bacteria in healthcare-associated pneumonia.
    Restrepo MI; Anzueto A
    Semin Respir Crit Care Med; 2009 Feb; 30(1):61-6. PubMed ID: 19199188
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging antibiotics for community-acquired pneumonia.
    Liapikou A; Cilloniz C; Palomeque A; Torres T
    Expert Opin Emerg Drugs; 2019 Dec; 24(4):221-231. PubMed ID: 31657962
    [No Abstract]   [Full Text] [Related]  

  • 31. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012).
    Farrell DJ; Sader HS; Flamm RK; Jones RN
    Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of ceftazidime/avibactam against Gram-negative pathogens isolated from pneumonia in hospitalised patients, including ventilated patients.
    Flamm RK; Nichols WW; Sader HS; Farrell DJ; Jones RN
    Int J Antimicrob Agents; 2016 Mar; 47(3):235-42. PubMed ID: 26920105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates--a multicentre, observational survey in critically ill patients.
    Vogelaers D; De Bels D; Forêt F; Cran S; Gilbert E; Schoonheydt K; Blot S;
    Int J Antimicrob Agents; 2010 Apr; 35(4):375-81. PubMed ID: 20122817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What is ventilator-associated pneumonia and why is it important?
    Kollef MH
    Respir Care; 2005 Jun; 50(6):714-21; discussion 721-4. PubMed ID: 15913464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis.
    Michalopoulos A; Kasiakou SK; Mastora Z; Rellos K; Kapaskelis AM; Falagas ME
    Crit Care; 2005 Feb; 9(1):R53-9. PubMed ID: 15693967
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.
    Lin SY; Huang CH; Ko WC; Chen YH; Hsueh PR
    Expert Opin Pharmacother; 2016; 17(3):339-54. PubMed ID: 26610040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of mechanical ventilation & development of multidrug resistant organisms in hospital acquired pneumonia.
    Mukhopadhyay C; Bhargava A; Ayyagari A
    Indian J Med Res; 2003 Dec; 118():229-35. PubMed ID: 14870795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ; Rybak JM; Rybak MJ
    Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling.
    Shen Y; Kuti JL
    Expert Opin Drug Metab Toxicol; 2023 Jan; 19(1):13-25. PubMed ID: 36786064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia.
    Rubinstein E; Corey GR; Stryjewski ME; Kanafani ZA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2737-50. PubMed ID: 22077833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.